Cyclerion is a clinical-stage biopharmaceutical company developing novel therapeutics for serious neuropsychiatric disorders, primarily focusing on CYC-126, a proprietary therapy for treatment-resistant depression that combines two established intravenous anesthetics with technology-enabled monitoring delivered in hospital settings. The company generates revenue through milestone payments and royalties from out-licensed assets including sGC stimulators with partners, while advancing its lead TRD program toward clinical trials. Cyclerion operates with a lean structure and is funded through equity financing, supported by intellectual property including licensed technology from academic partners and multiple issued and pending patents covering its therapeutic approaches.